CD8A and prostate cancer: In a xenograft mouse model of prostate cancer, transfer of tumor-reactive TGF-β-insensitive CD8+ T cells leads to a 50% decrease in average tumor weight, when compared with tumors of mice which underwent transfer of naïve CD8+ T cells [149].